Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

SymBio Pharmaceuticals (TYO: 4582)

Last close As at 21/11/2024

717.00

— 0.00 (0.00%)

Market capitalisation

27,591m

Edison Investment Research is terminating coverage on SymBio Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

SymBio Pharmaceuticals — The first whole quarter of internal SymBio sales

Healthcare | Update

SymBio Pharmaceuticals — Treakisym approved for DLBCL

Healthcare | Update

SymBio Pharmaceuticals — Now with commercial operations

Healthcare | Update

SymBio Pharmaceuticals — Treakisym RTD approved
Visit Website

Sector

Healthcare

Share Price Performance

Financials

Edison Investment Research is terminating coverage on SymBio Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Update

Healthcare

SymBio Pharmaceuticals — Treakisym has positive DLBCL results

Update

Healthcare

SymBio Pharmaceuticals — Treakisym has positive DLBCL results

Update

Healthcare

SymBio Pharmaceuticals — Guidance sinks on quality control issue

ADR Outlook

Healthcare

SymBio Pharmaceuticals — Looking forward to Treakisym Phase III data

Outlook

Healthcare

SymBio Pharmaceuticals — Looking forward to Treakisym Phase III data

ADR Update

Healthcare

SymBio Pharmaceuticals — Preparing to establish own sales organization

Update

Healthcare

SymBio Pharmaceuticals — Preparing to establish own sales organisation

ADR Outlook

Healthcare

SymBio Pharmaceuticals — Self-commercialization gains favor

Outlook

Healthcare

SymBio Pharmaceuticals — Self-commercialisation gains favour

ADR Update

Healthcare

SymBio Pharmaceuticals — Licence agreement for IONSYS terminated

Update

Healthcare

SymBio Pharmaceuticals — Licence agreement for IONSYS terminated

ADR Update

Healthcare

SymBio Pharmaceuticals — New formulations extend Treakisym patent life

ADR Outlook

Healthcare

SymBio Pharmaceuticals — Update 27 February 2017

research

Healthcare

SymBio Pharmaceuticals — Update 27 February 2017

Outlook

Healthcare

SymBio Pharmaceuticals — Update 27 February 2017

Flash note

Healthcare

SymBio Pharmaceuticals — Update 6 January 2017

ADR Update

Healthcare

SymBio Pharmaceuticals — Update 23 March 2016

Update

Healthcare

SymBio Pharmaceuticals — Update 21 March 2016

ADR Update

Healthcare

SymBio Pharmaceuticals — Update 30 November 2015

Update

Healthcare

SymBio Pharmaceuticals — Update 29 November 2015